Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen

Inclusion Criteria: * Healthy adults aged 18 to 50 years * Written informed consent * Resident in or near Oxford for the duration of the vaccination study * For women only, willingness to practice continuous effective contraception during the study and (if participating) during the subsequent challenge study. * Agreement to refrain from blood donation during the course of the study * Willingness to undergo an HIV test Exclusion Criteria: * Any deviation from the protocol defined normal range in biochemistry or haematology blood tests or in urine analysis * Prior receipt of an investigational malaria vaccine * Use of any investigational or non-registered drug, vaccine or medical device other than the study vaccine within 30 days preceding dosing of study vaccine, or planned use during the study period * Administration of chronic immunosuppressive drugs or other immune modifying drugs within six months of vaccination. * History of malaria chemoprophylaxis with chloroquine within 5 months prior to the planned challenge, with Lariam within 6 weeks prior to the challenge, and Riamet® within 2 weeks prior to the challenge * Any history of malaria * Travel to a malaria endemic area within the previous 6 months * Planned travel to malarious areas during the study period * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection and asplenia * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products * History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ) * History of haemoglobinopathies * History of diabetes mellitus * Chronic or active neurological disease * History of \> 2 hospitalisations for invasive bacterial infections * Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week * Seropositive for hepatitis B surface antigen (HBsAg) * Seropositive for hepatitis C virus (antibodies to HCV) * Hepatomegaly, right upper quadrant abdominal pain or tenderness * Evidence of serious psychiatric condition * Any on-going chronic illness requiring hospital specialist supervision * Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate * Pregnant or lactating woman * Any woman who is willing or intends to become pregnant during the study * Any history of anaphylaxis in reaction to vaccination * Principal Investigator assessment of lack of willingness to participate and comply with all requirements of the protocol * History or clinical evidence of intravenous drug abuse * Any other finding which in the opinion of the investigator would significantly increase the risk of having an adverse outcome from participating in this protocol